Gi Dynamics | search
Click here to view Gi Dynamics news from 60+ newspapers.
Bookmark or Share- GI Dynamics, Inc. Announces FDA Conditional Approval for Pivotal ...GI Dynamics, Inc. (ASX: GID) is pioneering the development and commercialization of effective, non-surgical treatments targeting the large and growing global patient populations with type 2 ...
- GI Dynamics, Inc. Receives FDA Approval to Commence Pivotal Clinical ...GI Dynamics, Inc. (ASX: GID) is pioneering the development and commercialization of effective, non-surgical treatments targeting the large and growing global patient populations with type 2 ...
- GI Dynamics wins FDA nod for pivotal US EndoBarrier trialGI Dynamics (ASX:GID) said today it won FDA investigational device exemption approval to launch a pivotal trial of its EndoBarrier device designed for treating patients with type 2 diabetes and...
- GI Dynamics Receives European CE Mark Approval for 12 Months of ...LEXINGTON, Mass.-- ( BUSINESS WIRE )-- GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval ...
- GI Dynamics Announces Company Rebrand as Morphic Medical® Reintroducing ...BOSTON, July 11, 2023 /PRNewswire/ -- GI Dynamics, creator of the world's first medical device designed to target the underlying cause of type 2 diabetes, is proud to announce its rebrand to ...
More
